Teva Pharmaceutical Industries Limited · TASE:TEVA
Teva Pharmaceutical Industries — 40th Annual J.P. Morgan Healthcare Conference (January 2022)
15 slides from Teva Pharmaceutical Industries's conference presentation, Jan 11, 2022
Slide 1: Teva Pharmaceutical Industries Ltd. J.P. Morgan Healthcare Conference
Teva Pharmaceutical Industries Ltd. J.P. Morgan Healthcare Conference Kåre Schultz President & CEO January 11, 2022
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainti
Slide 3: Opioids Litigation
Opioids Litigation – Investigations and early litigation (2014-2020) – Over 3,500 complaints filed by local, state and other governmental agencies, along with tribes and private plaintiffs, against various Teva affiliates and several other manufacturers, distributors and retailers: – 90% were consol
Slide 4: Opioids Litigation - Cont.
Opioids Litigation - Cont. – Trials/Appellate Decisions – J&J won appeal of trial verdict at Oklahoma Supreme Court; Court found public nuisance law inapplicable – Teva and co-defendants won in Orange County, CA; trial judge found that medicines sold lawfully could not be a basis of public nuisance
Slide 5: Strategy Update
Strategy Update Business optimization Debt and financing Future growth |5|
Slide 6: Operating Margin Expansion
Operating Margin Expansion Non-GAAP operating margin % 28.5% 28.0% 28.0% 27.8% 27.5% 27.0% 27.5% 26.8% 26.5% 26.3% Q3-21 26.0% 25.9% YTD 25.5% 25.0% 24.5% 24.5% 24.0% 2017 2018 2019 2020 2021 Guidance* 2023 Target |6| * Estimated margin based on 2021 guidance
Slide 7: Net Debt Development
Net Debt Development $ billions $36.0 $34 $34.0 $32.0 $30.0 $28.0 $26.0 $24.0 $22.0 $21.7 $20.0 Q3'17 Q4'17 Q1'18 Q2'18 Q3'18 Q4'18 Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 |7|
Slide 8: Successful Refinancing: $5B Sustainability-Linked Bond (SLB)
Successful Refinancing: $5B Sustainability-Linked Bond (SLB) ̶ Largest SLB of its kind ̶ First issued by a generic medicines company ̶ First in pharmaceutical industry to link both social and environmental targets ̶ Built on our strong ESG foundation and accelerates Teva’s ESG journey |8|
Slide 9: Debt Maturity Profile - Before & After the Refinancing
Debt Maturity Profile - Before & After the Refinancing Pre-Deal* Post-Deal** $ billions $ billions 4.5 3.6 3.5 3.5 3.5 3.0 3.0 2.0 2.1 2.1 2.1 2.0 2.0 2.0 1.7 1.4 1.2 1.0 0.8 0.8 0.8 21 22 23 24 25 26 27 28 … 36 … 46 21 22 23 24 25 26 27 28 29 30 … 36 … 46 Repurchased New Issued Total Debt Maturitie
Slide 10: AUSTEDO
® AUSTEDO® AUSTEDO TRx Count Per Month Highlights ̶ Monthly run rate of ~14K 14,042 prescriptions 14,000 ̶ Continued focus on patient activation 11,000 11,388 8,000 11/20 12/20 1/21 2/21 3/21 4/21 5/21 6/21 7/21 8/21 9/21 10/21 11/21 Source: IQVIA US NPA Audit | 10 |
Slide 11: AJOVY
AJOVY® AJOVY U.S Normalized TRx Share AJOVY EU Monthly Volume market share Highlights ̶ North America ̶ Quarterly normalized TRx volume growth 30.0% aligned with increases in market volume; 25% 27% 21.7% monthly normalized TRx share steady at 25.0% 21% 20% ̶ Europe 20.0% 15% ̶ 2nd leading brand in E
Slide 12: Teva Biosimilars
Teva Biosimilars A broad portfolio of 13 Biosimilars in Development: Truxima® – 7 in-house programs only rituximab biosimilar biosimilars through – 5 biosimilars with Alvotech partnerships and indicated for rheumatoid – 1 biosimilar with BioEq organic growth arthritis (RA) Rapidly Unique commercial
Slide 13: TV-46000 - Subcutaneous Risperidone ER for Patients with Schizophrenia
TV-46000 -Subcutaneous Risperidone ER for Patients with Schizophrenia NDA accepted by FDA. Expected action date in H1/22 Recently presented data showed TV-46000 decreased risk of relapse and increased chance of clinical stability versus placebo in patients with schizophrenia Committed to investigati
Slide 14: Long-Term Financial Targets
Long-Term Financial Targets To be achieved by year-end 2023 Operating income margin (2)(3) Cash-to-earnings(1)(3)(4) Net debt / EBITDA (3)(5) 28% >80% <3X Committed to utilizing cash flow to pay down debt; we do not plan to raise equity (1) Free cash flow includes cash flow from operating activities
Slide 15: Slide 15
Teva Pharmaceutical Industries — 40th Annual J.P. Morgan Healthcare Conference (January 2022) on 6ix